摘要
目的探讨医院获得性肺炎患者采用哌拉西林/他唑巴坦联合阿米卡星治疗的临床效果及安全性。方法 100例经确诊的医院获得性肺炎患者随机分为对照组50例和观察组50例。对照组患者仅应用哌拉西林/他唑巴坦给予治疗,观察组患者则联合使用哌拉西林/他唑巴坦和阿米卡星,将两组患者治疗后的临床效果、细菌学疗效及并发症进行对比。结果观察组患者平均住院时间[（8.01±2.01）d]明显少于对照组[（14.59±3.65）d],差异具有统计学意义（χ^2=4.5219,P=0.0387）;两组临床有效率（88.00%vs 92.00%）差异无统计学意义（χ^2=2.1637,P=0.1638）;观察组病原菌总清除率（89.58%）明显高于对照组（64.58%）,差异有统计学意义（χ^2=9.4138,P=0.0037）;两组不良反应发生率和护理满意度差异无统计学意义（χ^2=2.2134,P=0.1923;χ^2=1.6283,P=0.1524）。结论哌拉西林/他唑巴坦和阿米卡星联合治疗医院获得性肺炎具有显著的临床效果,对病原菌的清除率较高,可缩短患者住院时间,未发生严重的不良反应,建议推广。
Objective To investigate the clinical efficacy and safety of Piperacillin/tazobactam combined with Amikacin in the treatment of hospital-acquired pneumonia.Methods One hundred patients diagnosed as hospital-acquired pneumonia were randomly divided into a control group and an observation group respectively,with 50 patients in each group.Patients in control group were given Piperacillin/tazobactam alone,while those in observation group were treated with Piperacillin/tazobactam combined with Amikacin.The clinical effect,bacteriological efficacy and complications were compared between the two groups after treatment.Results The average length of stay in observation group was（8.01±2.01）days,which was significantly less than the（14.59±3.65）days in control group（χ^=4.5219,P=0.0387）.There was no significant difference in total clinical efficiency（88.00% vs 92.00%,χ^=2.1637,P=0.1638）.The total clearance of pathogens in observation group was 89.58%,significantly higher than that in control group（64.58%,χ^=9.4138,P=0.0037）.No significant differences in the incidence of adverse reactions and nursing satisfactions were seen.Conclusion Piperacillin/tazobactam combined with Amikacin has significant clinical efficacy for treating hospital-acquired pneumonia.It is characterized by high pathogen clearance rate,short hospital stay and no serious adverse reactions.
出处
《中国微生态学杂志》
CAS
CSCD
2016年第1期64-67,共4页
Chinese Journal of Microecology
